Blog
RSS FeedPosted by Michael Wonder on 24 Sep 2020
AstraZeneca boss says transparency key for vaccine
24 September 2020 - The chief executive of AstraZeneca has said the public must trust that multiple regulators will review ...
Posted by Michael Wonder on 22 Sep 2020
Taking steps toward transparency in real world evidence studies
22 September 2020 - The level of trust in health economics and outcomes research studies has been an on-going concern owing ...
Posted by Michael Wonder on 01 Sep 2020
Update on the agenda for the November 2020 PBAC meeting
1 September 2020 - Less than one week in and the agenda for the next scheduled PBAC meeting has already been ...
Posted by Michael Wonder on 24 Aug 2020
Insights from the July 2020 PBAC meeting - Insight #2 (agenda)
25 August 2020 - Agenda items are revised with no indication of what has been changed. ...
Posted by Michael Wonder on 20 Aug 2020
Swiss data protection chief pushes back on drug pricing secrecy
20 August 2020 - A proposed change to the new health insurance law that seeks to keep drug prices under lock ...
Posted by Michael Wonder on 06 Aug 2020
Italy becomes first country to require pharma to disclose public funding for R&D costs
6 August 2020 - Amid growing clamour for more transparency from the pharmaceutical industry, Italy has become the first country ...
Posted by Michael Wonder on 06 Aug 2020
Health experts to FDA: make your vaccine deliberations public
5 August 2020 - A letter signed by nearly 400 health experts asked the agency to use its vaccine advisory panel ...
Posted by Michael Wonder on 28 Jul 2020
2020 October price disclosure cycle – indicative prices
28 July 2020 - Indicative 1 October 2020 prices resulting from the 2020 October Cycle of Price Disclosure have now been ...
Posted by Michael Wonder on 23 Jul 2020
PBAC statement of endorsement for transparency measures and standardised redactions to public summary documents
23 July 2020 - The PBAC has made a statement outlining its support for measures to improve the transparency of ...
Posted by Michael Wonder on 25 Jun 2020
Price disclosure October 2020 cycle outcomes summary
25 June 2020 - The summary of price disclosure price reductions for the October 2020 Cycle has now been published. ...
Posted by Michael Wonder on 18 Jun 2020
US court nixes drug maker price disclosure
18 June 2020 - A US court has ruled against a move by President Donald Trump's administration to try to bring ...
Posted by Michael Wonder on 03 Jun 2020
EMA weighs COVID-19 data transparency, not ready to resume full clinical data publication
1 June 2020 - In a response to officials at Germany’s IQWiG and the Cochrane Collaboration, EMA Executive Director Guido ...
Posted by Michael Wonder on 14 May 2020
Emergency use authorisation of remdesivir: the need for a transparent distribution process
14 May 2020 - On 4 February 2020, the Secretary of the US Department of Health and Human Services (DHHS) determined ...
Posted by Michael Wonder on 12 May 2020
FDA's drug approval system is more open than Australia's
11 May 2020 - Australia’s secretive drug approval system gives what some believe is an unfair advantage to rival drug companies. ...
Posted by Michael Wonder on 03 May 2020
Agenda for the July 2020 PBAC meeting (revised)
1 May 2020 - Published on Wednesday and revised (with no notification) by Friday. ...